
CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and prog…
CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on … [+8282 chars]









